Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
Investing.com - Citizens JMP lowered its price target on Kura Oncology (NASDAQ:KURA) to $24.00 from $28.00 on Monday, while maintaining a Market Outperform rating on the stock. The company’s shares, currently trading at $5.54, have declined over 70% in the past year and are trading near their 52-week low of $5.41.
The price target reduction follows Kura’s second-quarter 2025 financial results and corporate updates, though the firm remains positive on the company’s outlook.
Citizens JMP cited its updated discounted EPS and revenue multiple analysis as the basis for the lower target, but emphasized that Kura shares still represent an attractive investment opportunity.
The firm noted that Kura’s lead drug candidate, zifto, remains on track for potential approval in the fourth quarter of 2025, with a PDUFA date of November 30.
Citizens JMP also highlighted Kura’s strong cash position of $630.7 million, which fully funds its planned front-line trials scheduled to begin in the second half of 2025.
In other recent news, Kura Oncology reported its Q2 2025 earnings, revealing a substantial shortfall in revenue expectations. The company posted actual revenue of $15.3 million, significantly below the forecasted $39.1 million, marking a 60.88% deficit. Additionally, the earnings per share (EPS) were lower than anticipated, with a reported loss of $0.75 compared to the expected loss of $0.41. These figures highlight the challenges Kura Oncology is currently facing in meeting financial projections. The earnings report has drawn attention from analysts and investors alike, as they assess the implications of these results. While the company’s stock experienced a minor decline in after-hours trading, the focus remains on the earnings and revenue figures. Investors are likely to keep a close watch on any further developments from the company. These recent developments underscore the importance of monitoring Kura Oncology’s financial performance closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.